Eisman J A, Suva L J, Sher E, Pearce P J, Funder J W, Martin T J
Cancer Res. 1981 Dec;41(12 Pt 1):5121-4.
Receptors for 1,25-dihydroxyvitamin D3 have been shown to exist in cultured breast cancer cells and in primary breast cancers. It is reported here that 1,25-dihydroxyvitamin D3 receptor (1,25-DR) was present in 80% of 54 unselected breast cancers. The concentration of 1,25-DR in the 43 receptor-positive tumors was 1.9 +/- 0.4 fmol/mg protein (S.E.). There was no correlation between 1,25-DR presence or concentration and the age of the patient or the concentration of estrogen, progesterone, androgen, or glucocorticoid receptors. 1,25-DR was also found in two of three renal cortical carcinomas but only in three of 14 gastrointestinal tract carcinomas. The relatively low concentration of 1,25-DR in these breast cancers, compared with that found in cultured breast cancer cells, is partially explained by incomplete "exchange" with occupied receptors. Since the serum vitamin D-binding protein is not precipitated from serum itself or from tissue homogenates using the polyethylene glycol method, artifactual 1,25-DR levels due to the inevitable contamination of tissue specimens with this protein can be excluded. These findings indicate that 1,25-DR is not a nonspecific marker of cancer. The high frequency of 1,25-DR in the breast cancers may be related to the calcium-transporting ability of breast cancer cells which allows them to grow as osteolytic metastases.
1,25 - 二羟维生素D3的受体已证实在培养的乳腺癌细胞和原发性乳腺癌中存在。本文报道在54例未经挑选的乳腺癌中,80%存在1,25 - 二羟维生素D3受体(1,25 - DR)。43例受体阳性肿瘤中1,25 - DR的浓度为1.9±0.4 fmol/mg蛋白质(标准误)。1,25 - DR的存在或浓度与患者年龄或雌激素、孕激素、雄激素或糖皮质激素受体的浓度之间无相关性。在三例肾皮质癌中有两例也发现了1,25 - DR,但在14例胃肠道癌中仅三例发现。与培养的乳腺癌细胞中发现的浓度相比,这些乳腺癌中1,25 - DR的浓度相对较低,部分原因是与被占据的受体不完全“交换”。由于使用聚乙二醇方法不能从血清本身或组织匀浆中沉淀出血清维生素D结合蛋白,因此可以排除因组织标本不可避免地被这种蛋白污染而导致的1,25 - DR水平的假象。这些发现表明1,25 - DR不是癌症的非特异性标志物。乳腺癌中1,25 - DR的高频率可能与乳腺癌细胞的钙转运能力有关,这使它们能够以溶骨性转移灶的形式生长。